VSIR and gastric cancer: Moreover, combination of VISTA blockade and PD‐1 inhibitor camrelizumab showed more significant apoptosis of tumour cells and reactivation of CD8+ T cells, compared with VISTA blockade or camrelizumab alone, suggesting a potential synergistic effect of VISTA blockade and PD‐1 inhibitor camrelizumab in gastric cancer.